medwireNews: The PD-L1 inhibitor atezolizumab has been approved in the USA as a first-line treatment for patients with extensive-stage small-cell lung cancer (SCLC) and should be given in combination with carboplatin and etoposide.
The approval follows results from the IMpower133 trial showing a significant improvement in overall and progression-free survival for atezolizumab plus carboplatin and etoposide compared with chemotherapy alone.
The recommended dose of atezolizumab is 1200 mg every 3 weeks initially given in a 60-minute infusion, with a 30-minute infusion permitted thereafter. If administered on the same day, chemotherapy should be given after atezolizumab treatment.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group